Use of myeloperoxidase (mpo) inhibitors or pharmaceutically acceptable salts thereof to treat multiple system atrophy (msa) 938
AssigneeAstraZeneca AB
InventorsHakan Eriksson, Werner Poewe
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of MPO inhibitors for the treatment of multiple system atrophy. The present invention also relates to the use of MPO inhibitors for the treatment of Huntington's disease. The present invention also relates to the use of MPO inhibitors for neuroprotection.
Claims4
1-7. (canceled)
A method for alleviating a symptom associated with multiple system atrophy, comprising administering to a subject an effective amount of a-compound, 1-(2-isopropoxyethyI)-2-thioxo-1,2,3,5-tetrahydro-pyrrolo[3,2-d]pyrimidin-4-one, or a pharmaceutically acceptable salt thereof, wherein the administration can provide a mean daily motor score in MSA mice of less than about 5.
-13. (canceled)
A method according to claim 1, wherein the effective amount of the compound, or the pharmaceutically acceptable salt thereof, is within the range of from 1 to 1000 mg.
Dependencies are inferred from the claim text.